CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

Depression is a pervasive mental health condition affecting millions of people worldwide. It can manifest in various ways, from persistent sadness to a lack of energy or interest in daily activities.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

Earlier phases of the trial showed promising results, with a single 25mg dose of COMP360 psilocybin, combined with psychological support, significantly reducing depressive symptoms after three weeks, ...